Detection of DNA crosslinks in peripheral lymphocytes isolated from patients treated with platinum derivates using modified comet assay

Neoplasma

Volumn 60, Issue 4, 2013, Pages 413-418

  Fikrova, P ^a   Stetina, R ^b   Hrnciarik, M ^c   Rehacek, V ^c   Jost, P ^d   Hronek, M ^a   Zadak, Z ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d Faculty of Health Sciences   (Czech Republic)

Author keywords

Cisplatin; Comet assay; DNA crosslinks

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMET ASSAY; DNA CROSS LINKING; DNA STRAND BREAKAGE; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL LYMPHOCYTE; DNA DAMAGE; DRUG EFFECT; GENETICS; HELA CELL; LUNG TUMOR; LYMPHOCYTE; METABOLISM; METHODOLOGY; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMET ASSAY; DNA DAMAGE; FEMALE; HELA CELLS; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED;

MLCS; MLOWN;

EID: 84880440451     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_053     Document Type: Article

References (29)

1. ALMEIDA GM, DUARTE TL, STEWARD WP, JONES GD: Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair 2005; 5, 219-225. http://dx.doi.org/10.1016/j.dnarep.2005.09.010
2. ROSENBERG B: Fundamental studies with cisplatin. Cancer 1985; 55, 2303-2316. http://dx.doi.org/10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L
3. LEBWOHL D, CANETTA R: Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998; 34, 1522-1534. http://dx.doi.org/10.1016/S0959-8049(98)00224-X
4. DRONKERT ML, KANNAR R: Repair of DNA interstrand cross-links. Mutation Research 2001; 486, 217-247. http://dx.doi.org/10.1016/S0921-8777(01)00092-1
5. UNGER FT, KLASEN HA, TCHARTCHIAN G, DE WILDE RL, WITTE I: DNA damage induced by cis-and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. BMC Cancer 2009; 9, 359. http://dx.doi.org/10.1186/1471-2407-9-359
6. RABIK CA, DOLAN ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Rev. 2007; 33, 9-23. http://dx.doi.org/10.1016/j.ctrv.2006.09.006
7. SINGH NP, MCCOY MT, TICE RR, SCHNEIDER EL: A simple technique for the quantitation of low levels of DNA damage in individual cells. Exp Cell Res, 1988; 175, 184-191. http://dx.doi.org/10.1016/0014-4827(88)90265-0
8. COLLINS AR: The comet assay for DNA damage and repair: principles, applications, and limitations. Mol. Biotechnol. 2004; 26, 249-261. http://dx.doi.org/10.1385/MB:26:3:249
9. MCKENNA DJ, MCKEOWN SR, MCKELVEY-MARTIN VJ: Potential use of the comet assay in the clinical management of cancer. Mutagenesis 2008; 23, 183-190. http://dx.doi.org/10.1093/mutage/gem054
10. HARTLEY JM, SPANSWICK VJ, GANDER M, GIACOMINI G, WHELAN J et al.: Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin. Cancer Res. 1999; 5, 507-512.
11. OLIVE PL, BANATH JP: Sizing highly fragmented DNA in individual apoptotic cells using the comet assay and a DNA crosslinking agent. Exp. Cell Res. 1995; 221, 19-26. http://dx.doi.org/10.1006/excr.1995.1348
12. PFUHLER S, WOLF U: Detection of DNA-crosslinking agents with alkaline comet assay. Environmental and Molecular Mutagenesis 1996; 27, 196-201. http://dx.doi.org/10.1002/(SICI)1098-2280(1996)27:3<196::AID-EM4>3.0.CO;2-D
13. ZHANG Z, HENG Z, HE F, PANG X: Detection of DNA crosslinks with comet assay. Wei Sheng Yan Jiu, 2001; 30, 146-148.
14. BASTLOVA T, VODICKA P, PETERKOVÁ K, HEMMINKI K, LAMBERT B: Styrene oxide-induced HPRT mutations, DNA adducts and DNA strand breaks in cultured human lymphocytes. Carcinogenesis 1995; 16, 2357-2362. http://dx.doi.org/10.1093/carcin/16.10.2357
15. KOHLEROVA R, STETINA R: The repair of DNA damage induced in human peripheral lymphocytes with styrene oxide. Acta Medica 2003; 46, 95-100.
16. DYPBUKT JM, COSTA LG, MANZO L, ORRENIUS S, NICORETA P: Cytotoxic and genotoxic effects of styrene-7,8-oxide in neuroadrenergic Pc 12 cells. Carcinogenesis 1992; 13, 417-424. http://dx.doi.org/10.1093/carcin/13.3.417
17. WALLES SAS, ORSEN I: Single-strand breaks in DNA of various organs of mice induced by styrene and styrene oxide. Cancer Letter 1983; 21, 9-15. http://dx.doi.org/10.1016/0304-3835(83)90076-9
18. VODICKA P, STETINA R, KUMAR R, PLNA K, HEMMINKU K: 7-Alkylguanine adducts of styrene oxide determined by 32P-postlabelling in DNA and human embryonal lung fibroblasts (HEL). Carcinogenesis 1996; 17, 801-808. http://dx.doi.org/10.1093/carcin/17.4.801
19. BOYUM A: Separation of white blood cells. Nature 1964; 204, 793-794. http://dx.doi.org/10.1038/204793a0
20. COLLINS AR, DOBSON VL, DUSINKSA M, KENNEDY G, STETINA R: The comet assay: what can it really tell us? Mutation Research 1997; 375, 183-193. http://dx.doi.org/10.1016/S0027-5107(97)00013-4
21. WYNNE P, NEWTON C, LEDERMANN JA, OLAITAN A, MOULD TA et al.: Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. British Journal of Cancer 2007; 97, 927-933.
22. ROBERTS JJ, FRIEDLOS F: Quantitative aspects of the formation and loss of DNA interstrand crosslinks in Chinese hamster cells following treatment with cis-diamminedichloroplatinu m(II) (cisplatin). I. Proportion of DNA-platinum reactions involved in DNA crosslinking. Biochemica et Biophysica Acta 1981; 655, 146-151. http://dx.doi.org/10.1016/0005-2787(81)90004-6
23. PASCOE JM, ROBERTS JJ: Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. Biochemical Pharmacology 1974; 23, 1345-1357. http://dx.doi.org/10.1016/0006-2952(74)90354-2
24. PENG B, TILBY MJ, ENGLISH MW, PRICE L, PEARSON AD et al.: Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer. 1997; 76, 1466-1473. http://dx.doi.org/10.1038/bjc.1997.579
25. KARTALOU M, ESSIGMANN JM: Mechanisms of resistance to cisplatin. Mutat. Res. 2001; 478, 23-43. http://dx.doi.org/10.1016/S0027-5107(01)00141-5
26. BOSKEN CH, WEI Q, AMOS CI, SPITZ MR: An analysis of DNA repair as a determinant of survival in patients with nonsmall-cell lung cancer. J Natl Cancer Inst. 2002; 94, 1091-1099. http://dx.doi.org/10.1093/jnci/94.14.1091
27. SANCHEZ-SUAREZ P, OSTROSKY-WEGMAN P, GALLEGOS-HERNANDEZ P, PENARROJA-FLORES R, TOLEDO-GARCIA J et al.: DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res. 2008; 640, 8-15. http://dx.doi.org/10.1016/j.mrfmmm.2007.11.008
28. REED E, YUSPA SH, ZWELLING LA, OZOLS RF, POIRIER MC: Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest. 1986; 77, 545-550. http://dx.doi.org/10.1172/JCI112335
29. PARKER RJ, GILL I, TARONE R, VIONNET JA, GRUNBERG S et al.: Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 1991; 12, 1253-1258. http://dx.doi.org/10.1093/carcin/12.7.1253